Myelodysplastic syndrome.
Pediatric myelodysplastic syndrome (MDS), though rare, constitutes a distinct entity quite different from adult MDS. They have unique clinical features, aggressive clinical course with an overall mean survival of only 9.9 months. A pediatric approach to the WHO classification has become necessary since the WHO classification of MDS has failed to address the uniqueness of pediatric MDS. A new prognostic system also needs to be evolved since the international prognostic system has limited prognostic impact in children. Intensive chemotherapy such as the one used in de novo-acute myeloid leukemia (AML) leads to complete remission in some children and this may be the treatment of choice in pediatric MDS.
Tilak
V
V
Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. vijaitilak@rediffmail.com
Sookmane
D D
DD
Gupta
V
V
Shukla
J
J
D000367:Age Factors; D002648:Child; D003937:Diagnosis, Differential; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis